Source comparison
Mechanism Comparison Table: MOTS-C vs. SS-31
Origin Encoded in mitochondrial 12S rRNA gene (natural peptide) Synthetic aromatic-cationic peptide (Szeto-Schiller family) Primary Localization Mitochondria → nucleus (stress-induced translocation) Inner mitochondrial membrane (cardiolipin-targeted) Primary M
This comparison does not assign a generated winner or score.
- Origin
- Encoded in mitochondrial 12S rRNA gene (natural peptide)
- Synthetic aromatic-cationic peptide (Szeto-Schiller family)
- Primary Localization
- Mitochondria → nucleus (stress-induced translocation)
- Inner mitochondrial membrane (cardiolipin-targeted)
- Primary Mechanism
- AMPK activation, Nrf2/ARE regulation, methionine-folate cycle modulation
- Cardiolipin stabilization, ETC supercomplex preservation, ROS reduction
- Metabolic Effects
- Improved glucose uptake, reduced lipogenesis, enhanced fat oxidation
- Indirect — improved ATP efficiency supports metabolic capacity
- Gene Regulation
- Yes — nuclear translocation modifies gene expression (AMPK targets, ARE genes)
- No direct nuclear gene regulation
- ROS Reduction
- Indirect — via Nrf2-mediated antioxidant enzyme upregulation
- Direct — reduces electron leak at ETC; scavenges mitochondrial ROS
- Mitochondrial Biogenesis
- Yes — AMPK→PGC-1α pathway activation
- Indirect — preserving existing mitochondria, reduces turnover demand
- Key Preclinical Models
- Diet-induced obesity, insulin resistance, aged skeletal muscle, exercise performance
- Cardiac ischemia-reperfusion, HFpEF, aged cardiac/skeletal muscle, renal ischemia
- Administration Route (Rodent)
- Subcutaneous injection (most studies)
- Subcutaneous injection or IP
- Age-Related Decline
- Yes — endogenous MOTS-C levels decline with aging
- Not applicable (synthetic compound)